![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 14, 2014 12:45:48 PM
However, some deductive reasoning. A partnership is only for a P2B trial, so a partnership is not needed, or warranted till a P2B is close to a start time/finalized, but needs to happen before the trial is finalized with the FDA because they will want to know what drugs are being used. The best deal will come when the best data is available.
So a final P2 is a must have
Interim expanded P2 would be nice but I don't think it is a requirement.
I can not think of any other events that have to happen as no other factors should play in to a P2B combination trial, maybe the P1 2 year survival data but that would be negligible. I don't expect a partnership till late Oct (just guess work, no reason) but I do believe that institutional buying will ramp up after P2 final is announced in the next few weeks.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM